66th ASH Annual Meeting: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I

Symposia: Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies Oral and Poster Abstracts
Poster

Research, Bleeding and Clotting, Bleeding disorders, Adult, Clinical Practice (Health Services and Quality), Hemophilia, Translational Research, Epidemiology, Clinical Research, Health outcomes research, Blood banking, Education, Supportive Care, Diseases, Patient-reported outcomes, Treatment Considerations, Young adult , Technology and Procedures, Study Population, Human

Halls G-H (San Diego Convention Center)

2251

Amaury Monard, MD^1,2^*, Sanne Tegels³^*, Inge Merry³^*, Floor Derikx³^*, Yvonne Henskens^4,5^*, Erik AM Beckers, MD, PhD⁶ and Floor CJI Moenen, MD, PhD⁷^*

¹Department of internal medicine, Maastricht University, Maastricht, AL, Belgium
²Carim- school for cardiovascular diseases, Maastricht, Netherlands
³Maastricht University Medical Center + (MUMC+), Maastricht, Netherlands
⁴CARIM - School for cardiovascular disease, Maastricht, Netherlands
⁵Maastricht UMC+, Maastricht, NLD
⁶Maastricht University Medical Center, Maastricht, NLD
⁷Department of Internal Medicine, Hematology, Maastricht University Medical Center+ and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Maastricht, Netherlands

2252

Risk Factors for Bleeding after Recent Medical Hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)

Mansour Gergi, MD¹, Katherine Wilkinson, MS²^*, Andrew Sparks, MS³^*, Nicholas S Roetker, PHD MS⁴^*, Hanny Al-Samkari, MD⁵, Nicholas L Smith⁶^*, Timothy B Plante¹^*, Mary Cushman¹, Allen B Repp, MD MSc¹^*, Chris E. Holmes, MD, PhD⁷, Karlyn A. Martin, MD, MS⁸ and Neil Zakai¹

¹University of Vermont, Burlington, VT
²University of Vermont Larner College of Medicine, Burlington, VT
³Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
⁴Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
⁵Division of Hematology, Massachusetts General Hospital, Cambridge, MA
⁶Department of Epidemiology, University of Washington, Seattle, WA
⁷Univ. of Vermont, Burlington, VT
⁸Division of Hematology and Oncology, University of Vermont Larner College of Medicine, Burlington, VT

2253

Addressing the Use of Direct Anticoagulants in Antiphospholipid Syndrome – Quality Improvement Initiative

Zoey I. Harris¹, Jan Anderson, PharmD, BCPS, BCACP, RPh²^*, Kathryn Taylor, PharmD, BCACP, RPh³^*, Evan Draper, PharmD, RPh³^*, Ana I. Casanegra, MD⁴^* and Surbhi Shah, MD⁵

¹Arizona, Mayo Clinic Arizona, Phoenix, AZ
²Division of Medicine, Mayo Clinic Minnesota, Rochester, MN
³Division of Medicine, Mayo Clinic Rochester, Rochester, MN
⁴Gonda Vascular Center, Mayo Clinic, Rochester, MN
⁵Arizona, Mayo Clinic, Scottsdale, AZ

2254

Implementing Evidence-Based Practices into Thrombophilia Order Sets: A Single Institution Quality Improvement Project

Lindsay Rivera, MD¹, James Davidson¹^*, Omar Alsharif¹^*, Albert Thomas Quiery, MD²^* and Heidi Worth, MD¹

¹University of Tennessee Medical Center, Knoxville, TN
²University of Tennessee Medical Center, Knoxville, AK

2255

Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study

Christian Kjellander, MD, PhD^1,2^*, Concetta Crivera, PharmD, MPH³^*, Ann Leon, PharmD³^*, Qian Cai, MPH, MSc³^*, Tina Jacob, PhD⁴^*, Erwei Zeng, PhD⁴^*, Christina V Jones, PhD⁴^*, Amy Leval, PhD⁵^*, Marie Fitzgibbon, MPharm, PhD, MBA⁶^*, Wim Noel, PhD⁷^*, Cathye Shu, MD, PhD⁸^* and Gunnar Larfors, MD, PhD⁹^*

¹Department of Internal Medicine, Capio St Göran Hospital, Stockholm, Sweden
²Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
³Janssen Global Services, LLC, a Johnson & Johnson company, Spring House, PA
⁴Schain Research AB, Stockholm, Sweden
⁵Janssen-Cilag AB, Solna, Sweden
⁶Janssen Pharmaceutica NV, Beerse, Belgium
⁷Medical Affairs Department, Janssen Pharmaceutica NV, Beerse, Belgium
⁸Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
⁹Department of Medical Sciences, Unit of Haematology, Uppsala University, Uppsala, Sweden

2256

Relationship between Frequency of Treatment Administration, Adherence to Treatment, and Quality of Life in Patients with Hemophilia a or Hemophilia B, with or without Inhibitors: A Real-World Survey

Erin Cockrell¹, Marion Afonso²^*, Kieran Wynne-Cattanach, MSc³^*, Sophie Lai, BSc⁴^*, Chris Blazos, BSc³^* and Giorgio Castellano³^*

¹St. Joseph's Children's Hospital, Tampa, FL
²Sanofi, Gentilly, France
³Adelphi Real World, Bollington, United Kingdom
⁴Adelphi Real World, Macclesfield, United Kingdom

2257

A Pilot Quality Improvement Initiative for Implementation of Venous Thromboembolism Prophylaxis for Patients with Gastrointestinal Malignancy

Austin Frisch, MD¹^*, Minira Aslanova, DO²^* and Upama Giri, MD³

¹Inova Fairfax, Falls Church, VA
²Inova Fairfax, Alexandria, VA
³Inova Schar Cancer Institute, Vienna, CA

2258

Starting a Blood Bank inside a Private Practice

Evelyn M Graham, MT (ASCP)¹^*, David Mark Graham, MD¹^*, Molly J Evans, MLS (ASCP) CM¹^*, Daniel Lucas Smith, MLS (ASCP)¹^*, Matthew Thomas Brinker¹^*, Erin M. Pettijohn, MD² and Thomas Edward Gribbin, MD¹^*

¹The Cancer and Hematology Centers, Grand Rapids, MI
²Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI

2259

Utilization and Clinical Outcomes of an Electronic Best Practice Alert to Prevent Venous Thromboembolism in High-Risk Cancer Patients

Kristi Upadhyaya^1,2^*, Mehrie H Patel¹^*, Xiaoying Chen³^*, Alok A. Khorana, MD¹ and Dana Elizabeth Angelini, MD¹

¹Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Taussig Cancer Institute, Cleveland Clinic Foundation, Troy, MI
³Cleveland Clinic, Quantitative Health Sciences, Lerner Research Institute, Cleveland, OH

2260

Classical Hematology: Not so Easy! Call for Expert!

Melissa Thomas, MD¹^*, Spencer Gibson, MD²^*, Arianna S Moss, BA³^*, Ray Quy, MD²^*, Eva Zhao, BS³^*, Angelina Wang, BS⁴^*, Ben P Debeusscher, BS⁴^* and Zahra Pakbaz, MD^5,6,7,8,9

¹Department of Internal Medicine, University California Irvine Health, Orange, CA
²Department of Internal Medicine, University of California Irvine Health, Orange, CA
³University of California Irvine School of Medicine, Irvine, CA
⁴Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange, CA
⁵University of California Irvine Medical Center, Orange, CA
⁶University of California Irvine, School of Medicine, Irvine
⁷Division of Hematology Oncology, University of California Irvine School of Medicine, Orange, CA
⁸Chao Family Comprehensive Cancer Center, Orange, CA
⁹Comprehensive CHAO family Cancer Center, University of California Irvine School of Medicine, Irvine, CA

2261

Routine Screening of African American Males in Hematology Oncology Clinic for G6PD Deficiency: A Prospective Comparative Study of a Pharmacogenomic Panel Versus Standard Enzyme Assay

Srishti Sareen, MD^1,2, Jaya Adabala^1,2^*, Katie Stoops^1,2^*, Jacob Marler¹^*, Lindsey Lands, MD^1,2^* and Alva Weir, MD^1,2^*

¹VA Medical Center, Memphis, TN
²UTHSC, Memphis, TN

2262

Real-World Analysis of Healthcare Resource Utilization in Patients with Hemophilia a and B with or without Inhibitors Using Data from Disease Specific Programmes™

Esteban Gomez, MD¹, Hanna Salehi, MSc²^*, Ella Morton, BSc³^* and Marion Afonso⁴^*

¹Center for Inherited Blood Disorders, Orange, CA
²Adelphi Real World, Bollington, United Kingdom
³Adelphi Real World, Macclesfield, United Kingdom
⁴Sanofi, Gentilly, France

2263

Retrieval Augmented Generation for the Detection of Major Bleeding Events in the Electronic Health Record

Peter Kaplinsky¹^*, Rohan Singh, MS¹^*, Thomas F Fusillo, DO, MS^1,2^*, Avi Leader, MD³, Jeffrey I. Zwicker, MD¹ and Simon Mantha, MD, MPH⁴

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside/West, New York, NY
³Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2264

Optimal Duration of Anticoagulation for Unprovoked Venous Thromboembolism: A Threshold Decision Analysis Model

Kimberley Youkhana, MD, MSCR¹, Charles Greenberg, MD² and Benjamin Djulbegovic, MD PhD²

¹Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC
²Medical University of South Carolina, Charleston, SC

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

901.P1.41 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I